TOP TEN perturbations for 38745_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38745_at
Selected probe(set): 201847_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38745_at (201847_at) across 6674 perturbations tested by GENEVESTIGATOR:
monocyte activation study 1 (NOD2L/TLR/1L; 6h) / untreated monocyte sample (6h)
Relative Expression (log2-ratio):-4.029112Number of Samples:5 / 5
| Experimental | monocyte activation study 1 (NOD2L/TLR/1L; 6h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1). | |
| Control | untreated monocyte sample (6h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 6 hours for RNA isolation. |
monocyte activation study 1 (NOD2L/TLR/1L; 24h) / untreated monocyte sample (24h)
Relative Expression (log2-ratio):-4.023323Number of Samples:5 / 5
| Experimental | monocyte activation study 1 (NOD2L/TLR/1L; 24h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1). | |
| Control | untreated monocyte sample (24h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 24 hours for RNA isolation. |
Sjogren's syndrome study 1 (advanced) / normal minor salivary gland tissue
Relative Expression (log2-ratio):3.8718872Number of Samples:2 / 4
| Experimental | Sjogren's syndrome study 1 (advanced) |
| Whole minor salivary gland samples of patients with advanced Sjogren's syndrome. | |
| Control | normal minor salivary gland tissue |
| Whole minor salivary gland samples from non-Sjogren's syndrome control subjects. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-3.720955Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):-3.3768015Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-3.2412853Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
monocyte activation study 1 (TLR/1L; 6h) / untreated monocyte sample (6h)
Relative Expression (log2-ratio):-3.2280731Number of Samples:5 / 5
| Experimental | monocyte activation study 1 (TLR/1L; 6h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1). | |
| Control | untreated monocyte sample (6h) |
| Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 6 hours for RNA isolation. |
DLBCL study 7 (GCB; plasmablast-like) / DLBCL study 7 (GCB; naive-like)
Relative Expression (log2-ratio):3.1516247Number of Samples:3 / 2
| Experimental | DLBCL study 7 (GCB; plasmablast-like) |
| Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to plasmablast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation. | |
| Control | DLBCL study 7 (GCB; naive-like) |
| Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation. |
ovarian tumor study 13 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-3.0537891Number of Samples:18 / 12
| Experimental | ovarian tumor study 13 |
| Human epithelial tumor cell samples from the ovary of patients with serous adenocarcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from healthy donors. Samples were derived by cell surface brushing. |
ovarian tumor study 25 (serous ovarian cancer epithelium) / normal ovarian surface epithelium cell sample
Relative Expression (log2-ratio):-2.8581734Number of Samples:12 / 12
| Experimental | ovarian tumor study 25 (serous ovarian cancer epithelium) |
| Laser capture micro-dissected serous ovarian cancer epithelium cells derived from female individuals with primary papillary serous adenocarcinoma of the ovary. | |
| Control | normal ovarian surface epithelium cell sample |
| Normal ovarian surface epithelium cell (OSE) samples isolated from female individuals by laser capture micro-dissection (LCM). Indication for removal of healthy ovaries were others than ovary cancer. |